Seeking a basis for pharmaceutical products from algae and other organisms in the sea

October 13, 2010

Researchers at the Faculty of Pharmacy at the University of Helsinki are co-ordinating an extensive project which aims to find biological activity from among organisms in the sea which would be suitable for use as a basis for pharmaceutical products. Interesting compounds isolated from organisms in the sea are chemically modified to be more suitable for medical purposes.

The four-year (2010-2014) MAREX project involves researchers and corporate sector representatives from 13 countries. In the project's total budget of EUR 7.9 million, EUR 6 million originates from the Seventh Framework Programme of the European Union. MAREX is co-ordinated by Heikki Vuorela, Professor at the Faculty of Pharmacy. The journey to the shelves of chemists is long, but the extensive and carefully planned project has good opportunities for interesting active compounds for the development of pharmaceuticals against cancer, microbes or pain.

The project researchers all around the world start off with sampling. Among other things, they collect micro- and macro-algae, sea anemones, tunicates and fish from the Atlantic, the Pacific, the Mediterranean and the Baltic Sea. Collecting the samples does not harm the ecosystems. Some research teams also have existing sample collections. However, the main focus of the project is on materials which have not previously been tested. The objective is to utilise organisms and populations (e.g., blue-green algae and macro algae) which are usually considered as insignificant and harmful. Already at the collecting stage, ready products are the aim.

"Right from the start, we will consider whether an algae or other raw material from the sea may be utilised on an industrial scale. It is not enough that the material has potential to be a cancer pharmaceutical. Instead, it must be available or it must be possible to produce it in sufficiently large quantities," says Päivi Tammela, researcher at the Faculty of Pharmacy.

According to Paula Kiuru, researcher at the Faculty of Pharmacy, and Jari Yli-Kauhaluoma, Professor, compounds obtained from sea organisms usually have a very complex chemical structure. The goal is to identify the most important structural parts of the most interesting compounds. With the information, it will be possible to considerably simplify the structure of a complex compound while retaining the original biological activity.

Other Finnish contributors to the project in addition to the University of Helsinki include Åbo Akademi University and the VTT Technical Research Centre of Finland. In addition to co-ordination, the task of the researchers at the University of Helsinki is to study the antimicrobial characteristics of the samples and develop synthetic derivatives. The project kick-off seminar in Helsinki was attended by researcher and corporate sector representatives from many European countries, as well as from India, Lebanon and Turkey.
-end-
For more information on the MAREX project (Exploring Marine Resources for Bioactive Compounds: From Discovery to Sustainable Production and Industrial Applications), please contact:

Professor Heikki Vuorela
Faculty of Pharmacy
00014 University of Helsinki
E-mail: heikki.vuorela@helsinki.fi
Telephone +358405 516 502

University of Helsinki

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.